Carmel Diagnostics ltd. Israel

Carmel Diagnostics is a medtech company who developed an innovative method for measuring Oxidative Stress (OS) of a biological liquid, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet simple technology. Carmel’s lead product is Embryo Selection in IVF process. Carmel won the prestigious Phase-2 grant from Horizon2020, planning market launch in H1/2021. It has an experienced, motivated team.

Company Size (Fulltime employees)
Year of foundation
2009
Please specify your partnering goal
Potential licensing
Funding Status
Series A, looking for an investment of 4M USD
Now raising (In USD)
5M
Headquartner in China
Plan in China
We have already registered WFOE in China. Our plans are:Establish Manufacturing site and customer support in ChinaFertissimo distribution in China to improve IVF performancePromote Additional applications in cooperation with Chinese Institutes/Academy/IndustryPromote the use of AI, Bioinformatics and machine learning for optimization and continuous improvement
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
Fertissimo TCL Analyzer. CE Mark
Medtech Development Stage
Slides Deck
(pptx, 7.32MB)
Mr Tzali Cnaani
LinkedIn logo CEO 
Functionality

Glenpharma AB Sweden

   Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders. 

We offer patented synergistic combinations of biopolymers for 

a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) .  The product accelerates healing at least 3 times faster than the normal healing process. 

b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.

c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA)  .  Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation. 

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.

All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities".  Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.

Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China. 

Company Size (Fulltime employees)
Year of foundation
2002
Please specify your partnering goal
To develop and market above projects under exclusive license for China .
Headquartner in China
Assets Information 1: Name|Description|Indications|Stage|IP countries
Patents|Novel formulations of biopolymers for repair of injuries to connective tissue|Injuries involving tendons / ligaments , etc in sports injuries, elderly patients, joint disease ( arthritis ) , major surgery.|USA, Canada, Europe, China, Australia, etc
Biotech/Pharma Asset Stage
Medtech Development Stage
Target Client Type
Pharma / Device companies working with orthopedics or major surgery
Slides Deck
(pdf, 600.02KB)
Senior Scientist Peter Buckley
CEO 
Functionality

Global Clinical Trials (GCT) United States

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.
Company Size (Fulltime employees)
Year of foundation
2001
Stock Market and Ticker/Symbol/Number
N/A
Please specify your partnering goal
Networking, new business opportunities
Headquartner in China
Plan in China
GCT is looking for potential new business opportunities, offering full-service clinical trials support worldwide for Chinese pharma companies.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Development Stage
Your Service Name
clinical trials, market authorization, registration, consulting
Service Description
logistics, regulatory services, project and site management, pharmacovigilance, medical monitoring, data management, biostatistics, medical writing, GDPR and DPO, EU Legal representation,
Target Client Type
Pharma, Biotech, Device companies
Aleksandr Stiblo
LinkedIn logo Director, Business Development 
Functionality

Strategikon Pharma United States

Strategikon Pharma is the developer of Clinical Maestro™, which is an end-to-end elegant cloud-based platform to more efficiently budget, source and manage complex clinical programs. We believe that intuitive technology, complete transparency and effective communication between biopharmaceutical companies and providers will revolutionize the productivity of clinical research.

Clinical Maestro™: Modernize the outsourcing
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Build awareness of Clinical Maestro value
Headquartner in China
Biotech/Pharma Asset Stage
Medtech Development Stage
Mengdie Peng
Business Development Manager 
Functionality